- Home
- DHI vs ARGX Comparison
DHI vs ARGX Comparison
Compare DHI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHI
- ARGX
- Stock Information
- Founded
- DHI 1978
- ARGX 2008
- Country
- DHI United States
- ARGX Netherlands
- Employees
- DHI N/A
- ARGX N/A
- Industry
- DHI Homebuilding
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHI Consumer Discretionary
- ARGX Health Care
- Exchange
- DHI Nasdaq
- ARGX Nasdaq
- Market Cap
- DHI 44.0B
- ARGX 40.4B
- IPO Year
- DHI 1992
- ARGX 2017
- Fundamental
- Price
- DHI $127.38
- ARGX $572.52
- Analyst Decision
- DHI Buy
- ARGX Strong Buy
- Analyst Count
- DHI 16
- ARGX 20
- Target Price
- DHI $173.13
- ARGX $682.00
- AVG Volume (30 Days)
- DHI 3.3M
- ARGX 325.0K
- Earning Date
- DHI 04-17-2025
- ARGX 05-08-2025
- Dividend Yield
- DHI 1.26%
- ARGX N/A
- EPS Growth
- DHI 1.87
- ARGX N/A
- EPS
- DHI 14.16
- ARGX 12.78
- Revenue
- DHI $36,688,400,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- DHI $0.52
- ARGX $57.86
- Revenue Next Year
- DHI $4.96
- ARGX $31.90
- P/E Ratio
- DHI $8.99
- ARGX $43.01
- Revenue Growth
- DHI 2.12
- ARGX 77.22
- 52 Week Low
- DHI $124.23
- ARGX $352.77
- 52 Week High
- DHI $199.85
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- DHI 44.66
- ARGX 43.11
- Support Level
- DHI $124.38
- ARGX $574.81
- Resistance Level
- DHI $132.53
- ARGX $598.06
- Average True Range (ATR)
- DHI 3.34
- ARGX 12.69
- MACD
- DHI 0.05
- ARGX -0.16
- Stochastic Oscillator
- DHI 31.28
- ARGX 36.55
About DHI D.R. Horton Inc.
D.R. Horton is a leading homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.